Drug development: The cell wall as a drug target  by Cox, Jonathan A.G.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y x x x ( 2 0 1 6 ) x x x –x x x
.sc ienced i rec t .comAvai lab le a t wwwScienceDirect
journal homepage: www.elsevier .com/ locate / IJMYCODrug development: The cell wall as a drug targethttp://dx.doi.org/10.1016/j.ijmyco.2016.09.012
E-mail address: j.a.g.cox@aston.ac.uk
Peer review under responsibility of Asian African Society for Mycobacteriology.
Please cite this article in press as: JAG Cox. Drug development: The cell wall as a drug target. Int. J. Mycobacteriol. (2016), http://d
10.1016/j.ijmyco.2016.09.012Jonathan A.G. Cox
School of Life & Health Sciences, Aston University, Birmingham, UKThe complex and essential cell wall ofMycobacterium tuber-
culosis represents a plethora of new and old drug targets that
collectively form an apparent mycobacterial ‘‘Achilles’ heel”.
The mycolic acids are long-chain a-alkyl-b-hydroxy fatty
acids (C70–90), which are unique to mycobacterial species,
forming an integral component of the mycolyl–arabinogalac-
tan–peptidoglycan complex. Their apparent uniqueness to
the M. tuberculosis complex has rendered components of
mycolic acid biosynthesis as powerful drug targets for specific
tuberculosis (TB) chemotherapy. Here, I will discuss a contri-
bution to TB drug discovery by deconvolution of the inhibitory
mechanisms of a number of antitubercular compounds tar-
geting mycolic acid biosynthesis. I will begin with the early
days, elucidating the mode of action of ethionamide [1] and
thiolactomycin [2], each targeting two separate components
of the fatty acid synthase II (FAS-II) pathway. I will further dis-
cuss the recently discovered tetrahydropyrazo[1,5-a]pyrim-
idine-3-carboxamide compounds [3] which selectively target
the essential, catalytically silentM. tuberculosis EchA6, provid-
ing a crucial lipid shunt between b-oxidation and FAS-II and
supplying lipid precursors for essential mycolate biosynthe-
sis. Finally, I will discuss the recent discovery of the mode
of action of the indazole sulfonamides [4], inhibiting M. tuber-
culosis KasA by, a completely novel inhibitory mechanism.Conflict of interest
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